Geometry.Net - Health_Conditions: Myelodysplastic Syndromes


Home - Health_Conditions - Myelodysplastic Syndromes

e99.com Bookstore

Images

Newsgroups

61-80 of 102 Back | 1 | 2 | 3 | 4 | 5 | 6 | Next 20

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Myelodysplastic Syndromes: more books (49)

Gale Encyclopedia of Medicine: Sideroblastic anemia by Maureen Haggerty, 2002-01-01
Paraoxysmal Nocturnal Hemoglobinuria and Related Disorders
Hematopoietic Lineages in Health and Disease by Testa, 1997-04-01
Chronic Myeloid Neoplasias and Clonal Overlap Syndromes: Epidemiology, Pathophysiology and Treatment Options by Richard Greil, Lisa Pleyer, et all 2010-06-07
Across the Chasm: A Caregiver's Story by Naomi L. Zikmund-Fisher, 2002-02-01
Needs assessment of families who have children with myelodysplasia by Nyla Juhl, 1992
Myelodysplasia and the leukemias (Current problems in cancer) by Peter Jacobs, 1998

lists with details

HighWire -- Browse Journals - Myelodysplastic Syndromes
Browse Journals publishing on myelodysplastic syndromes, (return to Topic Journals focusing on myelodysplastic syndromes (in order by highest focus)
http://highwire.stanford.edu/lists/topic_dir/608683/608684/613947/613948/614293/

Extractions: Chronic Myelomonocytic Leukemia (CMML) Refractory Anemia Sort by: Alphabet Frequency of articles in Myelodysplastic Syndromes Focus of journal on Myelodysplastic Syndromes What's this? Journals focusing on Myelodysplastic Syndromes (in order by highest focus) ASH Education Program Book info free SITE Journal of Medical Genetics ... Hematologic Cancers and Related Disorders Myelodysplastic Syndromes Home Adv. Search For Institutions For Publishers ... partners/suppliers
Search Result For "Myelodysplastic Syndromes"
Aplastic Anemia and myelodysplastic syndromes; Myelodysplasia; Myelodysplastic What is Myelodysplastic Syndrome?; Do We Know What Causes Myelodysplastic
http://www.noah-health.org/search/results.php?lang=1&keyword=Myelodysplastic Syn
Anomalies ClassifMDSID1239
The concept of myelodysplastic syndromes has evolved gradually from the description Proposals for the classification of the myelodysplastic syndromes.
http://www.infobiogen.fr/services/chromcancer/Anomalies/ClassifMDSID1239.html

Extractions: The classification of acute myeloid leukemia (AML) and myelodysplasic syndromes (MDS) includes clinical data (previous history, age) and biologic characteristics (morphology, cytochemistry, immunophenotype, cytogenetic and molecular biology). The separation of homogeneous classes allows us to distinguish pronostic parameters and to identify groups of patients sensitive to drugs or to specific treatment. Recurrent cytogenetic abnormalities are strong prognostic indicators in AML and MDS. Molecular studies of structural chromosomal changes have enabled the cloning of genes located at chromosomal breakpoints and have helped to characterize the proteins involved in leukemogenesis. Morphologic studies remain important because of a strong correlation with cytogenetic and molecular abnormalities. Clinics and Pathology Note The myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by cytopenia and bone marrow dysplasia. This is resulting from proliferation, differentiation and apoptotic processes of hematopoietic precursors with frequent evolution to acute myeloid leukemia (AML). Anemia, neutropenia or thrombocytopenia, separated or in combination, despite a hyper or normo-cellular bone marrow, define MDS. The concept of myelodysplastic syndromes has evolved gradually from the description of a group of anemias previously described as "refractory anemias".
Anomalies ChildMDS
myelodysplastic syndromes in childhood. Report of 21 patients from Italy myelodysplastic syndromes in childhood a population based study of nine cases.
http://www.infobiogen.fr/services/chromcancer/Anomalies/childMDS.html
Myelodysplastic Syndromes - Cambridge University Press
The chapters cover all aspects of the myelodysplastic syndromes, Clinical andprognostic characterization of Myelodysplastic Syndrome Peter Greenberg;
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521496683
Elsevier.com - Myelodysplastic Syndrome And Cytokines
Myelodysplastic syndrome (MDS) is thought to be an incurable disease typified by Possible pathophysiological roles of GCSF in myelodysplastic syndromes
http://www.elsevier.com/wps/product/librarians/522353

Extractions: Home Site map Regional Sites Advanced Product Search ... Myelodysplastic Syndrome and Cytokines Book information Product description Author information and services Ordering information Bibliographic and ordering information Conditions of sale Book related information Submit your book proposal Other books in same subject area About Elsevier Select your view MYELODYSPLASTIC SYNDROME AND CYTOKINES Myelodysplastic syndrome (MDS) is thought to be an incurable disease typified by a clonal disorder in the maturation and proliferation stage of multipotential hematopoietic stem cells. The three main themes in this book are: Influence of cytokines on the maturation and proliferation of normal hematopoietic progenitor cells as well as leukemic cells including those from patients with MDS. Synergisms of cytokines in vitro and in vivo. Clinical features of MDS including BMT. The book provides useful information regarding effective treatments of MDS based on a better understanding of the cytokine actions as well as the association with the hematopoiesis including the network system.
Cancer Symptoms Treatments - Dana-Farber Cancer Institute
Secondary myelodysplastic syndromes develop following treatment with radiation There are treatments for all patients with myelodysplastic syndromes.
http://www.dana-farber.org/can/cancer/Default.asp?doc=CDR62723.xml&type=summary&
Methodist Healthcare - Services
April 2005, Dacogen Effective in myelodysplastic syndromes. January 2005,Vidaza Approved for myelodysplastic syndromes
http://www.methodisthealth.org/service.asp?id=canCin&fid=MedicalServices&CC_OB=_
Myelodysplastic Syndrome
Lewis S, Wainscoat JS, Moore NR, Golding SJ. Magnetic resonance imaging inmyelodysplastic syndromes. Br J Radiol 1995 Feb;68(806)1217 UI95253709
http://home.earthlink.net/~radiologist/tf/031300.htm

Extractions: This 77 y/o female presented with left hip pain and anemia after a fall. Plain films demonstrated some degenerative osteoarthritic changes but were otherwise unremarkable. An MRI with coronal T1 and fat saturated inversion recovery and axial proton density and fat saturated T2 weighted sequences was performed. Selected images from the MRI scan shown above demonstrate diffuse abnormal marrow signal and abnormal signal in the obturator internus. The abnormal signal in the obturator was felt to be due to muscle strain and was likely the cause of the acute left hip symptoms. Bone marrow biopsy and subsequent consultation with the Hematopathology Department at City of Hope National Medical Center with immunostains and expert morphologic review of peripheral blood and marrow led to the diagnosis of myelodysplastic syndrome. Lewis S, Wainscoat JS, Moore NR, Golding SJ. Magnetic resonance imaging in myelodysplastic syndromes. Br J Radiol 1995 Feb;68(806):121-7 UI:95253709 Takagi S, Tanaka O, Origasa H, Miura Y. Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. J Clin Oncol 1999 Jan;17(1):277-83 UI:99385425 Kusumoto S, Jinnai I, Matsuda A, Murohashi I, Bessho M, Saito M, Hirashima K, Heshiki A, Minamihisamatsu M. Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome: observations with magnetic resonance imaging. Eur J Haematol 1997 Sep;59(3):155-61 UI:97455911
Log In Problems
The first drug in a new class of compounds shows promise for treating these commonhematologic disorders.
http://www.medscape.com/viewarticle/509073?rss
LII - Results For "myelodysplastic Syndromes"
The myelodysplastic syndromes Foundation. MDS, or myelodysplastic syndromes, isa collection of disorders in which the bone marrow does not produce enough
http://www.lii.org/advanced?searchtype=subject;query=Myelodysplastic syndromes;s
HONmeeting - Health Conferences & Event- Myelodysplastic Syndromes
Want more events about myelodysplastic syndromes in your mailbox? click here for myelodysplastic syndromes with HONselect.
http://www.hon.ch/Conf/Theme/C15.378.190.625.html
ASH Image Bank - Case Study
Myelodysplastic Syndrome. Atlas image, Stanley Schrier Achievements inUnderstanding and Treatment of myelodysplastic syndromes
http://www.ashimagebank.org/fullcase.asp?case_id=100508
Myelodysplastic Syndromes And Myeloproliferative Disorders; Free, Interactive Te
The Leukemia Lymphoma Society, the leading source of information and supportfor patients battling leukemia, lymphoma and myeloma, in collaboration with
http://www.medicalnewstoday.com/medicalnews.php?newsid=12379
Clinical Trial: Infliximab In Treating Patients With Myelodysplastic Syndrome
de novo myelodysplastic syndromes secondary myelodysplastic syndromes previouslytreated myelodysplastic syndromes, Drug infliximab
http://www.clinicaltrials.gov/ct/gui/show/NCT00074074

Extractions: Verified by National Cancer Institute (NCI) May 2005 Sponsored by: European Organization for Research and Treatment of Cancer Information provided by: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Purpose RATIONALE: Monoclonal antibodies, such as infliximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of infliximab in treating patients who have myelodysplastic syndrome. Condition Intervention Phase refractory anemia with excess blasts Study Design: Treatment Official Title: Phase II Randomized Study of Infliximab in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes Further Study Details: OBJECTIVES: Determine the therapeutic activity of 2 different doses of infliximab on peripheral blood cell count and peripheral and bone marrow blast cell count in patients with low- or intermediate-risk myelodysplastic syndromes.
Clinical Trial: Decitabine In Treating Patients With Myelodysplastic Syndromes O
myelodysplastic and myeloproliferative disease myelodysplastic syndromes One of the following diagnoses; Highrisk myelodysplastic syndromes (MDS)
http://www.clinicaltrials.gov/ct/gui/show/NCT00049582

Extractions: Verified by National Cancer Institute (NCI) April 2005 Sponsors and Collaborators: Princess Margaret Hospital National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Purpose RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of decitabine in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Condition Intervention Phase adult acute myeloid leukemia Study Design: Treatment Official Title: Phase I Study of Decitabine in Patients With High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia Further Study Details: OBJECTIVES: Determine the maximum tolerated dose of decitabine in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia.
BioMed Central | Full Text | Pediatric Myelodysplastic Syndromes
myelodysplastic syndromes (MDS) are clonal disorders characterized by myelodysplastic syndromes with less than 5% blasts in the bone marrow are
http://www.biomedcentral.com/1527-2729/6/209

Extractions: home journals A-Z subject areas advanced search ... my BioMed Central To obtain access to Current Treatment Options in Oncology through your institution use the options below. If you would like information about a personal subscription, please contact subs@phl.cursci.com Click here to view an abstract of this article Click here to login if you are already a subscriber to Current Treatment Options in Oncology Subscribe to Current Treatment Options in Oncology Register for a free online trial Ask your librarian to investigate institutional access Athens users please click here to gain access If you believe you are seeing this page in error,
BioMed Central | Full Text | New Agents In Myelodysplastic Syndromes
To obtain access to Current Hematology Reports through your institution use theoptions below. If you would like information about a personal subscription,
http://www.biomedcentral.com/1540-3408/4/191

Extractions: home journals A-Z subject areas advanced search ... my BioMed Central To obtain access to Current Hematology Reports through your institution use the options below. If you would like information about a personal subscription, please contact subs@phl.cursci.com Click here to view an abstract of this article Click here to login if you are already a subscriber to Current Hematology Reports Subscribe to Current Hematology Reports Register for a free online trial Ask your librarian to investigate institutional access Athens users please click here to gain access If you believe you are seeing this page in error,
PharmGKB: Myelodysplastic Syndromes
Dysmyelopoietic Syndromes; Myelodysplastic Syndrome; Syndrome, Dysmyelopoietic;Syndrome, Myelodysplastic; Syndromes, Dysmyelopoietic; Syndromes,
http://www.pharmgkb.org/do/serve?objId=PA445013&objCls=Disease
Disease Category Listing (516): Myelodysplastic Syndromes (MDS)
CenterWatch Listing of Clinical Research Trials for myelodysplastic syndromes (MDS)
http://www.centerwatch.com/patient/studies/cat516.html

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

61-80 of 102 Back | 1 | 2 | 3 | 4 | 5 | 6 | Next 20